输注器精密有限公司美股招股说明书(2025-06-13版)

This Prospectus Supplement amends and supplements the Prospectus dated January 22, 2025, filed with the Securities and Exchange Commission as part of the registration statement on Form S-3 (333-284217). It relates to the offer and sale of shares of the company's common stock under the At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. as the sales agent.

Key points:

• The company has sold a total of 2,884,909 shares of common stock for gross proceeds of approximately $1,290,116 through Ladenburg Thalmann & Co. Inc. under the Agreement during the 12 months prior to and including the date of this Prospectus Supplement.
• As of June 11, 2025, the aggregate market value of the company's common stock held by non-affiliates is $9,557,387, based on 15,928,979 shares outstanding at $0.60 per share.
• The company is currently permitted to offer and sell shares of common stock with an aggregate offering price of up to $1,895,679 under the terms of the Agreement and General Instruction I.B.6 of Form S-3.
• The company will not sell securities in public primary offerings on Form S-3 with a value exceeding one-third of its public float in any 12-month period as long as its public float remains below $75.0 million.
• If the company's public float increases above $75.0 million, it will no longer be subject to the limits in General Instruction I.B.6 of Form S-3. Any additional sales under the Agreement would require the filing of another prospectus supplement.
• The company's common stock trades on the NYSE American under the symbol “VTAK,” with the last reported sale price on June 12, 2025, being $0.4232 per share.
• Investing in the company's common stock involves a high degree of risk, and investors are advised to carefully consider the risk factors discussed in the “Risk Factors” section of the ATM Prospectus.

The Prospectus Supplement is not complete without the ATM Prospectus and may only be delivered or utilized in connection with it.